Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An unusually "complex" glomerulonephritis.

Proceedings (Baylor University. Medical Center)·2022

Same author

Rheumatoid Arthritis: Early Diagnosis and Treatment.

Rheumatic diseases clinics of North America·2022

Same author

Systemic Lupus Erythematosus Management in Pregnancy.

International journal of women's health·2022

Same author

Rheumatoid Arthritis: Early Diagnosis and Treatment.

The Medical clinics of North America·2021

Same author

A paraneoplastic syndrome exacerbated by checkpoint inhibition therapy.

Proceedings (Baylor University. Medical Center)·2021

Same author

EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer.

Nature cancer·2020

Search research articles

Related Experiment Video

Updated: May 17, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Malignancy risks with biologic therapies.

John J Cush¹, Kathryn H Dao

¹Baylor Research Institute, Dallas, TX 75229, USA. jjcush@gmail.com

Rheumatic Diseases Clinics of North America

|November 10, 2012

Summary

Biologic drugs transformed rheumatoid arthritis (RA) treatment but may increase cancer risk. This review examines current data on the short- and long-term cancer risks associated with these important RA therapies.

Area of Science:

Immunology
Rheumatology
Oncology

Background:

Biologic agents like etanercept and infliximab revolutionized rheumatoid arthritis (RA) and Crohn's disease management starting in 1998.
Currently, nine biologic agents are available for RA treatment, offering significant therapeutic advancements.
Concerns exist regarding the potential for long-term biologic use to impair immunosurveillance and elevate cancer risk in patients.

Purpose of the Study:

To review and synthesize the current evidence on the association between biologic therapies for RA and cancer risk.
To clarify whether observed malignancies are attributable to rheumatoid arthritis itself or its treatments.

Main Methods:

Literature review of studies investigating cancer incidence in patients treated with biologic agents for RA.

Related Experiment Videos

Last Updated: May 17, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Analysis of data focusing on both short-term and long-term cancer risks.

Examination of the potential mechanisms linking biologic therapy to altered immunosurveillance and malignancy.

Main Results:

Growing body of data suggests a potential link between biologic use in RA and cancer risk.
Distinguishing between RA-related inflammation and therapy-induced risk remains a complex challenge.
Evidence is accumulating on the specific short- and long-term cancer risks associated with different biologic agents.

Conclusions:

Biologic therapies for RA, while effective, warrant careful consideration regarding their long-term safety profile, particularly concerning cancer risk.
Further research is needed to fully elucidate the complex relationship between RA, its treatments, and malignancy.
Ongoing monitoring and risk-benefit assessment are crucial for patients receiving biologic therapy for rheumatoid arthritis.